IP Library › Granted Patent US 10,220,000
Granted Patent B2
US 10,220,000 · App. 15/847,350 · Granted Mar 5, 2019

Methods and compositions for X-ray induced release from pH sensitive liposomes

Inventors: Daniel Fologea (Boise, ID); Ralph Henry (Fayetteville, AR); Greg Salamo (Fayetteville, AR); Yuriy Mazur (Fayetteville, AR); Michael J. Borrelli (Little Rock, AR)
Assignees: The Board of Trustees of the University of Arkansas; BioVentures, LLC
A61K9/1271A61K9/0009A61K45/06A61K47/10A61N5/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,220,000
App. No.
15/847,350
Granted
Mar 5, 2019
Kind
B2
Abstract

Compositions including pH sensitive lipid vesicles comprised of a lipid layer, an agent, and an organic halogen such that the agent is released from the vesicles after exposure to ionizing radiation. Methods of delivering the agent to a target in a subject using the compositions provided herein are also described. The methods allow for controlled release of the agent. The timing of release of the agent from the lipid vesicle may be controlled as well as the location of release by timing and localizing the exposure to ionizing radiation exposure.

Claims (25)

1. A pH sensitive lipid vesicle composition configured for the controlled release of an agent upon exposure to ionizing radiation, the composition comprising:

a lipid layer, the lipid layer comprising a pH sensitive phospholipid selected from the group consisting of a phosphatidylethanolamine, a phosphatidylcholine, and a combination thereof, and

an aqueous medium, the aqueous medium comprises the agent and an organic halogen capable of interacting with ionizing radiation to increase the acidity of the aqueous medium,

wherein the organic halogen is selected from chloral hydrate and bromal hydrate and has a concentration between 0.01 M and 2 M in the aqueous medium within the vesicle.

2. The composition of claim 1 , wherein the pH sensitive phospholipid is selected from the combination of the phosphatidylethanolamine and the phosphatidylcholine.

3. The composition of claim 1 , wherein the lipid layer further comprises a member selected from a lipid anchored polyethylene glycol, cholesterol, a targeting molecule, a pH sensitive polymer, a polypeptide capable of localizing in the lipid layer, and any combination thereof.

4. The composition of claim 3 , wherein the lipid layer comprises the lipid anchored polyethylene glycol, cholesterol, or both the lipid anchored polyethylene glycol and cholesterol.

5. The composition of claim 3 , wherein the targeting molecule is selected from a targeting polypeptide, a folate receptor, an antibody, and any combination thereof.

6. The composition of claim 3 , wherein the pH sensitive polymer comprises a pH sensitive moiety selected from the group consisting of methylacrylic acid, ethylacrylic acid, propylacrylic acid, butylacrylic acid, and any combination thereof.

7. The composition of claim 1 , wherein the agent is selected from a group consisting of a cancer therapeutic agent, a polypeptide, a toxin, a radiotherapeutic agent, a radiosensitizing agent, an angiogenesis inhibitor, an imaging agent, and any combination thereof.

8. The composition of claim 3 , wherein the molar ratio of the pH sensitive lipid, the lipid anchored polyethylene glycol, cholesterol, the targeting molecule, the pH sensitive polymer, and the polypeptide capable of localizing in the lipid layer is configured to initiate sustained release of the agent following exposure to ionizing radiation while sealing the lipid layer prior to exposure to ionizing radiation at an initial pH.

9. The composition of claim 1 , wherein the aqueous medium has a concentration of organic halogen configured to initiate sustained release of the agent following exposure to ionizing radiation while sealing the lipid layer prior to exposure to ionizing radiation at an initial pH.

10. The composition of claim 1 , wherein the composition is configured release at least 25% of the agent within 4 hours of interacting with ionizing radiation.

11. The composition of claim 1 , wherein the composition is configured to release at least 50% of the agent within 8 hours of interacting with ionizing radiation.

12. A pH sensitive lipid vesicle composition configured for the controlled release of an agent upon exposure to ionizing radiation, the composition comprising:

a lipid layer, the lipid layer comprising a pH sensitive phospholipid selected from the group consisting of a phosphatidylethanolamine, a phosphatidylcholine, and a combination thereof, a lipid anchored polyethylene glycol, and cholesterol, and an aqueous medium, the aqueous medium comprises the agent and an organic halogen capable of interacting with ionizing radiation to increase the acidity of the aqueous medium,

wherein the organic halogen is selected from chloral hydrate and bromal hydrate and has a concentration between 0.01 M and 2 M in the aqueous medium within the vesicle.

13. The composition of claim 12 , wherein the pH sensitive phospholipid is selected from the combination of the phosphatidylethanolamine and the phosphatidylcholine.

14. The composition of claim 12 , wherein the molar ratio of the pH sensitive lipid, the lipid anchored polyethylene glycol, and cholesterol in the lipid layer is configured to initiate sustained release of the agent following exposure to ionizing radiation while sealing the lipid layer prior to exposure to ionizing radiation at an initial pH.

15. The composition of claim 12 , wherein the aqueous medium has a concentration of organic halogen configured to initiate sustained release of the agent following exposure to ionizing radiation while sealing the lipid layer prior to exposure to ionizing radiation at an initial pH.

16. A method for the localized release of an agent within a subject, the method comprising:

administering a pH sensitive lipid vesicle composition as in claim 1 to a subject and exposing a portion of the subject to ionizing radiation whereby interaction of the composition to the ionizing radiation within the exposed portion of the subject initiates the release of agent from the composition.

17. The method of claim 16 , wherein the molar ratio of the pH sensitive lipid in the lipid layer is configured to initiate sustained release of the agent following exposure to ionizing radiation while sealing the lipid layer prior to exposure to ionizing radiation within the subject.

18. The method of claim 16 , wherein the aqueous medium has a concentration of organic halogen configured to initiate sustained release of the agent following exposure to ionizing radiation while sealing the lipid layer prior to exposure to ionizing radiation within the subject.

19. The method of claim 16 , wherein the lipid layer further comprises a lipid anchored polyethylene glycol and cholesterol.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 047861 FRAME 0828. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEES ARE THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS AND BIOVENTURES, LLC. Recorded Jan 3, 2019
From: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS; BIOVENTURES, LLC
Reel/Frame 049355/0131 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2018
From: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
To: BIOVENTURES, LLC
Reel/Frame 047861/0828 →
CORRECTIVE ASSIGNMENT TO CORRECT THE FIFTH ASSIGNOR'S NAME PREVIOUSLY RECORDED AT REEL: 046527 FRAME: 0174. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 10, 2018
From: FOLOGEA, DANIEL; HENRY, RALPH; SALAMO, GREG; MAZUR, YURIY; BORRELLI, MICHAEL J.
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Reel/Frame 047043/0899 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2018
From: FOLOGEA, DANIEL; HENRY, RALPH; SALAMO, GREG; MAZUR, YURIY
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Reel/Frame 046527/0174 →
Continuity (3)
Continuation 14357038
Provisional Application 61556936 · Nov 8, 2011
Related Publication 20180104188A1 · Apr 19, 2018
Cited By (1)
US 12,595,407